BCRX Biocryst Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BCRX

Price (delayed)

$11.34

Market cap

$2.01B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.09

Enterprise value

$2.01B

Sector: Healthcare
Industry: Biotechnology
Website: https://www.biocryst.com/

Highlights

Biocryst Pharmaceuticals's quick ratio has surged by 119% QoQ and by 71% YoY
BCRX's equity has dropped by 157% since the previous quarter and by 150% year-on-year
The net income has dropped by 68% year-on-year and by 46% since the previous quarter

Key stats

What are the main financial stats of BCRX
Market
Shares outstanding
177.18M
Market cap
$2.01B
Enterprise value
$2.01B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
106.49
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
113.09
Earnings
Revenue
$17.81M
EBIT
-$168.31M
EBITDA
-$167.57M
Free cash flow
-$137.73M
Per share
EPS
-$1.09
Free cash flow per share
-$0.82
Book value per share
-$0.11
Revenue per share
$0.11
TBVPS
$2
Balance sheet
Total assets
$334.72M
Total liabilities
$353.98M
Debt
$279.5M
Equity
-$19.26M
Working capital
$218.15M
Liquidity
Debt to equity
-14.51
Current ratio
3.06
Quick ratio
2.95
Net debt/EBITDA
-0.03
Margins
EBITDA margin
-940.7%
Gross margin
90.6%
Net margin
-1,026.4%
Operating margin
-981.1%
Efficiency
Return on assets
-84.8%
Return on equity
-773.6%
Return on invested capital
-205.1%
Return on capital employed
-73.5%
Return on sales
-944.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BCRX stock price

How has the Biocryst Pharmaceuticals stock price performed over time
Intraday
0.89%
1 week
19.37%
1 month
-14.35%
1 year
237.5%
YTD
52.21%
QTD
11.5%

Financial performance

How have Biocryst Pharmaceuticals's revenue and profit performed over time
Revenue
$17.81M
Gross profit
$16.14M
Operating income
-$174.76M
Net income
-$182.81M
Gross margin
90.6%
Net margin
-1,026.4%
BCRX's operating income has shrunk by 76% YoY and by 43% QoQ
The net income has dropped by 68% year-on-year and by 46% since the previous quarter
Biocryst Pharmaceuticals's gross profit has plunged by 67% from the previous quarter and by 64% YoY
BCRX's revenue has shrunk by 67% QoQ and by 64% YoY

Growth

What is Biocryst Pharmaceuticals's growth rate over time

Valuation

What is Biocryst Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
106.49
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
113.09
BCRX's EPS has plunged by 51% from the previous quarter and by 16% YoY
BCRX's equity has dropped by 157% since the previous quarter and by 150% year-on-year
BCRX's revenue has shrunk by 67% QoQ and by 64% YoY

Efficiency

How efficient is Biocryst Pharmaceuticals business performance
Biocryst Pharmaceuticals's ROE has plunged by 135% from the previous quarter but it has soared by 82% YoY
The ROIC has shrunk by 66% YoY but it rose by 34% QoQ
The company's return on assets fell by 19% QoQ and by 2% YoY

Dividends

What is BCRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BCRX.

Financial health

How did Biocryst Pharmaceuticals financials performed over time
Biocryst Pharmaceuticals's total assets is 5% lower than its total liabilities
The total liabilities has soared by 158% YoY and by 148% from the previous quarter
Biocryst Pharmaceuticals's quick ratio has surged by 119% QoQ and by 71% YoY
BCRX's equity has dropped by 157% since the previous quarter and by 150% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.